



YOUR EXPERIENCE

in the use of PrBOTOX® (onabotulinumtoxinA) for the following indications:

Focal spasticity

- The management of focal spasticity, including the treatment of upper limb spasticity associated with stroke in adults
- The symptomatic treatment of lower limb spasticity associated with stroke in adults
- Symptomatic treatment of upper and/or lower limb spasticity in pediatric patients two years of age or older. BOTOX is not intended as a replacement for usual standard of care regimens and is not likely to be effective in improving range of motion at a joint affected by a fixed contracture

Blepharospasm

- The treatment of blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age or older

Cervical dystonia

- To reduce the subjective symptoms and objective signs of cervical dystonia (spasmodic torticollis) in adults

OUR COMMITMENT

to raising awareness and providing education for patients and healthcare professionals throughout the treatment journey, including:

-  Ongoing support with our AbbVie Care Support Program
-  Public and private coverage across Canada (criteria applies)
-  Disease awareness through patient organizations
-  Healthcare professional education
-  Local, regional and national events
-  Presence at national congresses



For more information:

Please consult the Product Monograph at: https://www.abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/products/BOTOX_PM_EN.pdf for contraindications, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use, which have not been discussed in this piece. The Product Monograph is also available by calling 1-800-668-6424.

REFERENCE: Current BOTOX Product Monograph, AbbVie Corporation.

BOTOX and its design are trademarks of AbbVie Corporation.
© 2022 AbbVie. All rights reserved.

abbvie

